MOTS-c, Epithalon, and the emerging longevity peptide literature — what the animal data shows and where the gaps remain.
The longevity field is, at its best, a careful enterprise concerned with the slow biology of aging — mitochondrial decline, telomere attrition, accumulated damage to DNA and protein, the gradual loss of regenerative capacity. At its worst, it is a marketing engine attached to a small number of underexamined compounds. Both versions exist simultaneously in the peptide market.
This is a brief, honest reading of the research on three of the most-discussed longevity-adjacent compounds in the catalog: NAD+, MOTS-c, and Epithalon. None of them is a cure for aging. Each of them has a real, if partial, scientific case.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It participates in hundreds of metabolic reactions, most importantly in the electron transport chain that generates cellular energy in mitochondria. It is also the substrate consumed by the sirtuin family of enzymes — the “longevity enzymes” popularized by Sinclair and others — and by PARP enzymes involved in DNA repair.
NAD+ levels decline with age, in human tissues and in nearly every animal model studied. The decline correlates with reduced mitochondrial function, impaired DNA repair capacity, and many of the hallmarks of cellular aging. The argument for NAD+ restoration is that replenishing the pool may slow or partially reverse some of these declines.
The evidence is strongest in animal models, where NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) have been shown to extend healthspan and, in some studies, lifespan in mice. Human evidence is more limited but generally favorable on biomarkers — improved mitochondrial markers, reduced inflammation, improved insulin sensitivity in some populations. Hard clinical endpoints (disease incidence, mortality) require very long trials that have not been completed.
NAD+ itself, injected subcutaneously, is one approach to restoration. Whether direct NAD+ administration is preferable to precursor supplementation (NR or NMN) is an active question; the pharmacokinetics differ and the evidence is still being collected.
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial DNA itself — one of a small family of mitochondrial-derived peptides discovered relatively recently. Its functional role appears to be as a metabolic signaling molecule: MOTS-c influences cellular metabolism, AMPK activation, glucose uptake, and metabolic stress response.
The interest in MOTS-c as a longevity compound comes from two findings. First, circulating MOTS-c levels decline with age in humans — mirroring NAD+. Second, exogenous MOTS-c administration in aged mice has been shown to improve metabolic markers, exercise capacity, and several measures of healthspan. The 2021 Reynolds et al. study in Nature Communications showed restoration of physical performance in aged mice that resembles a younger phenotype on multiple measures.
Human data is sparse. The compound is an active research interest but is not approved for any clinical indication. Its long-term safety profile in humans is not formally established.
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in the laboratory of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the 1980s. The peptide is derived from the natural pineal hormone epithalamin, with the active sequence isolated and synthesized.
The Khavinson laboratory has published several long-term studies, mostly in elderly Russian populations, reporting that Epithalon administration over years was associated with reduced all-cause mortality, improved physiological markers, and in cell-culture work, telomerase activation and extended replicative lifespan. The most cited cellular finding is that Epithalon induces telomerase expression and reactivates telomerase activity in somatic cells, which would in principle slow the cellular aging process associated with telomere shortening.
The Russian clinical literature is extensive but has not been replicated in Western trials at comparable scale. The telomerase findings have been demonstrated in human cell lines but the translation to in vivo telomere maintenance in humans is less well-characterized. Epithalon remains a fascinating compound whose Western evidence base lags significantly behind its Russian one.
Three things are true about longevity peptide research that the marketing rarely admits.
The animal evidence is genuine. The mouse work on NAD+ precursors, on MOTS-c, on Epithalon, is real. It is published in respectable journals by respectable laboratories. Healthspan extension in mice is repeatable across compounds in this class. This is not nothing.
The human evidence is preliminary. Mouse work translates to humans only partially and unpredictably. The compounds in this category are mostly at the stage where biomarkers improve in short human studies, but hard clinical endpoints (extended life, prevented disease) require trials that have not been done at adequate scale or duration.
The biology is sound. Mitochondrial decline, NAD+ depletion, telomere attrition — these are real, well-characterized features of aging. Compounds that act on these processes have a plausible mechanism. Plausible mechanism is necessary but not sufficient.
The honest position on these peptides is that they sit in an interesting space between “definitely effective for aging” (no human compound is at this level yet) and “completely unsupported” (they are not). The serious researchers in this field treat the compounds as tools for exploring specific biological pathways, not as anti-aging medicines.
Lumira's longevity catalog includes NAD+ 500mg, MOTS-c in 10mg and 40mg vials, and Epithalon in 10mg and 50mg vials. For primary literature, the Sinclair laboratory at Harvard has published extensively on NAD+ biology; the Cohen laboratory at USC on MOTS-c and the mitochondrial-derived peptides; and the Khavinson group in St. Petersburg on Epithalon.
This article is provided for informational and educational purposes only. Lumira Labs products are sold strictly for laboratory research use and are not for human consumption, medical use, or veterinary application. The compounds discussed are not approved by Health Canada or the FDA for any therapeutic indication. Nothing in this article should be construed as medical advice.